SG11202110055SA - Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof - Google Patents

Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof

Info

Publication number
SG11202110055SA
SG11202110055SA SG11202110055SA SG11202110055SA SG11202110055SA SG 11202110055S A SG11202110055S A SG 11202110055SA SG 11202110055S A SG11202110055S A SG 11202110055SA SG 11202110055S A SG11202110055S A SG 11202110055SA SG 11202110055S A SG11202110055S A SG 11202110055SA
Authority
SG
Singapore
Prior art keywords
preparation
crystal form
method therefor
phosphodiesterase inhibitor
phosphodiesterase
Prior art date
Application number
SG11202110055SA
Other languages
English (en)
Inventor
Zhonghui Wan
Lin Li
Original Assignee
Transthera Sciences Nanjing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transthera Sciences Nanjing Inc filed Critical Transthera Sciences Nanjing Inc
Publication of SG11202110055SA publication Critical patent/SG11202110055SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202110055SA 2019-03-15 2020-03-13 Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof SG11202110055SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910199611 2019-03-15
CN201910228418 2019-03-25
CN201910789020 2019-08-26
PCT/CN2020/079337 WO2020187165A1 (fr) 2019-03-15 2020-03-13 Forme cristalline d'un inhibiteur de phosphodiestérase, son procédé de préparation et son utilisation

Publications (1)

Publication Number Publication Date
SG11202110055SA true SG11202110055SA (en) 2021-10-28

Family

ID=72476356

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110055SA SG11202110055SA (en) 2019-03-15 2020-03-13 Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof

Country Status (12)

Country Link
US (1) US20230125064A2 (fr)
EP (1) EP3939978A4 (fr)
JP (1) JP7326662B2 (fr)
KR (1) KR20210138689A (fr)
CN (1) CN111689958B (fr)
AU (1) AU2020242652B2 (fr)
BR (1) BR112021018357A2 (fr)
CA (1) CA3133717C (fr)
SG (1) SG11202110055SA (fr)
TW (1) TWI830884B (fr)
WO (1) WO2020187165A1 (fr)
ZA (1) ZA202107810B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3373838B2 (ja) 1999-10-25 2003-02-04 山之内製薬株式会社 ナフチリジン誘導体
AR029185A1 (es) * 1999-10-25 2003-06-18 Yamanouchi Pharma Co Ltd Derivado de naftiridina
WO2017019723A1 (fr) * 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Aza-cyanoquinolinone utiles en tant qu'inhibiteurs de pde9
US10370337B2 (en) 2015-07-29 2019-08-06 Merck, Sharp & Dohme Corp. Oxy-cyanoquinolinone PDE9 inhibitors
WO2017019724A1 (fr) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Phénylcyanoquinolinones utiles en tant qu'inhibiteurs de pde9
CN109575016B (zh) * 2017-09-28 2022-01-04 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
CN107605187A (zh) 2017-09-30 2018-01-19 伍京栋 一种可调节水温和水位的家庭儿童泳池
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途

Also Published As

Publication number Publication date
EP3939978A1 (fr) 2022-01-19
BR112021018357A2 (pt) 2021-11-23
CN111689958B (zh) 2021-11-19
KR20210138689A (ko) 2021-11-19
US20220194934A1 (en) 2022-06-23
WO2020187165A1 (fr) 2020-09-24
JP7326662B2 (ja) 2023-08-16
CA3133717A1 (fr) 2020-09-24
US20230125064A2 (en) 2023-04-20
AU2020242652A1 (en) 2021-10-28
CN111689958A (zh) 2020-09-22
CA3133717C (fr) 2023-12-05
TW202102496A (zh) 2021-01-16
EP3939978A4 (fr) 2023-01-04
ZA202107810B (en) 2022-08-31
JP2022534641A (ja) 2022-08-03
TWI830884B (zh) 2024-02-01
AU2020242652B2 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
EP3743063A4 (fr) Inhibiteurs de cbl-b et leurs procédés d'utilisation
EP4034094A4 (fr) Inhibiteurs de phosphodiestérase et leur utilisation
IL287751A (en) kcnt1 inhibitors and methods of use
EP3502113A4 (fr) Sel pharmaceutiquement acceptable d'inhibiteur d'egfr, forme cristalline de celui-ci, son procédé de préparation et son application
IL287768A (en) kcnt1 inhibitors and methods of use
EP3810617A4 (fr) Inhibiteurs d'ectonucléotidases et leurs procédés d'utilisation
IL287973A (en) acss2 inhibitors and methods of their use
EP3986894A4 (fr) Inhibiteurs d'ectonucléotidases et leurs procédés d'utilisation
EP3812378A4 (fr) Formes cristallines de l'arn-509, procédé de préparation correspondant et utilisation associée
EP4059926A4 (fr) Forme cristalline de tafamidis ainsi que son procédé de préparation et son utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
IL286697A (en) Neurogulin-4 compounds and methods of use
IL264854A (en) Spt5 inhibitors and methods of use thereof
IL287293A (en) RNA editing inhibitors and methods of use
IL286485A (en) pi4-kinase inhibitors and methods of using them
EP3755689A4 (fr) Inhibiteurs de l'egfr et leurs procédés d'utilisation
EP3959197A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
IL289586A (en) pi4kiii alpha micromolecule inhibiting preparation, method for its preparation and use
EP3755690A4 (fr) Inhibiteurs d'egfr et leurs procédés d'utilisation
GB2589398B (en) Compounds and methods of use
ZA202107810B (en) Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof
EP3674304A4 (fr) Forme cristalline d'un inhibiteur de parp-1 et son procédé de préparation
EP4286377A4 (fr) Forme cristalline de resmetirom, son procédé de préparation et son utilisation
ZA202003581B (en) Crystal form of urat1 inhibitor, and preparation method therefor
EP3968994C0 (fr) Inhibiteurs abhd12 et leurs procédés de fabrication et d'utilisation